Patent Application
20120015923
The invention relates to compounds for the treatment of airway disorders such as asthma and chronic obstructive pulmonary disease.
Airway disorders such as asthma and chronic obstructive pulmonary disease (COPD) afflict a large number of people. At present, there are about 300 million people worldwide suffering from asthma. It is predicted that the prevalence will go up to 400 million by 2025. Asthma is a common chronic lung disease of the airways that is complex and characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness (bronchospasm), and an underlying inflammation. The interaction of these features of asthma determines the clinical manifestations and severity of asthma and the response to treatment. The rising incidence and prevalence of asthma worldwide have signalled for a need to develop better therapeutic agents. The pathophysiology of asthma is multifactorial, involving a complex network of immune responses and reactions. Furthermore, exposure to uncertained environmental factors can lead to different asthmatic responses in people with dissimilar genetic backgrounds. All these contribute to the uncertainties in asthmatic occurrence, thus making the control of asthma difficult.
Asthma is a chronic airway disorder characterized by airway inflammation, mucus hypersecretion, and airway hyperresponsiveness (AHR)1. The precise mechanisms that lead to the occurrence of AHR are not fully understood yet, but it is found to be related to the inflammation response mediated by mast cells and eosinophils. Cumulative evidence revealed that these inflammatory responses are mediated by T-helper type 2 (Th2) cells together with mast cells, B cells and eosinophils, as well as a number of inflammatory cytokines and chemokines1-2. IL-4 is imperative for B cell isotype switching for the synthesis of immunoglobulin (Ig)E. Allergen-induced crosslinking of IgE-bound high affinity IgE receptors (FcεRI) on the surface of mast cells leads to degranulation and activation of mast cells, and the release of inflammatory mediators like histamine, leukotrienes and cytokines, and immediate broncho-constriction3-4. IL4 5 is vital for the growth, differentiation, recruitment, and survival of eosinophils which contribute to inflammation and even airway remodeling in asthma5. IL-13 plays a pivotal role in the effector phase of Th2 responses such as eosinophilic inflammation, mucus hypersecretion, AHR and airway remodeling6. In addition, chemokines such as RANTES (regulated on activation, normal T cells expressed and secreted) and eotaxin are crucial to the delivery of eosinophils to the airways7. Airway eosinophilia, together with Th2 cytokines IL-4, IL-5 and IL-13, may ultimately contribute to AHR in asthma8. Persistent activation of nuclear factor (NF)-κB has been associated with the development of asthma.
Current therapy for asthma comprises of bronchodilators and anti-inflammatory agents. Currently there are three anti-Inflammatory agents for controlling asthma, which Include 1) Inhaled steroids, 2) cysteinyl-leukotriene receptor antagonist and 3) cromolyn. However, the therapeutic efficacies of cysteinyl-leukotriene receptor antagonist and cromolyn are highly variable and may be limited to certain subgroup of patients. Inhaled corticosteroid, helps to suppress inflammation and reduces the swelling of the lining of the airways, however the glucocorticoid usage is associated with major side effects, and about 5-10% asthmatics are steroid-resistant. Corticosteroid-resistant patients present considerable management problems as there are few alternative anti-inflammatory treatments available58.
The first line therapy for the control of mild to severe asthma patients involves the usage of a combination of high-dose inhaled corticosteroids (CS) and long-acting β2-agonists (LABAs). Patients with severe persistent asthma often require additional medications, such as anti-leukotrines and anti-IgE therapies. Glucocorticoid is most commonly used in treating asthma, and inhaled corticosteroids have become established as first-line treatment in patients with persistent asthma21. Nonetheless, there is a small proportion (5-10%) of asthmatic patients fail to respond to glucocorticoid even at high doses or with supplementary therapy22. Moreover, there has been increasing concern over the side effects of CS such as osteoporosis, glaucoma, weight gain, reduced bone density, muscle breakdown, anovulation, growth retardation in children and poor wound healing effects15. As prescribing a higher dose of LABA could lead to the occurrence of undesirable side effects, it is thus generally recommended that LABA should be used together with CS or theophylline for better treatment. Although the combination of CS and LABA is by far the most successful treatment used in treating asthma, the occurrence of adverse effects make it necessary to have alternatives treatments for asthma.
Chronic obstructive pulmonary disease (COPD) refers to chronic bronchitis and emphysema, two commonly co-existing diseases of the lungs in which the airways become narrowed (14). This leads to a limitation of the flow of air to and from the lungs causing shortness of breath. In contrast to asthma, the limitation of airflow is poorly reversible and usually gets progressively worse over time.
COPD is caused by noxious particles or gas, most commonly from tobacco smoking, which triggers an abnormal inflammatory response in the lung. The natural course of COPD is characterized by occasional sudden worsening of symptoms called acute exacerbations, most of which are caused by infections or air pollution. COPD is also known as chronic obstructive lung disease (COLD), chronic obstructive airway disease (COAD), chronic airflow limitation (CAL) and chronic obstructive respiratory disease (CORD).
There is currently no cure for COPD and the only measures that have been shown to reduce mortality are smoking cessation and supplemental oxygen (14). COPD can be managed with bronchodilators such as β2 agonists and/or anticholinergics. β2 agonist stimulate β2 receptors while anticholinergics block stimulation from cholinergic nerves both are medicines that relax smooth muscle around the airways, increasing air flow. There are several β2 agonists available, salbutamol or albuterol and terbutaline are widely used short acting β2 agonists and provide rapid relief of COPD symptoms. Long acting β2 agonists (LABAs) such as salmeterol and formoterol are used as maintenance therapy. Ipratropium is the most widely prescribed short acting anticholinergic drug. Anticholinergics appear to be superior to β32 agonists in COPD, however both β2 agonists and anticholinergics do not have anti-inflammatory actions and they do not halt progression of COPD.
Andrographolide is a labdane diterpenoid that is the main bioactive component of the medicinal plant Andrographis paniculata (Burm. f.) Nees, (Acanthaceae). Andrographolide is an extremely bitter substance extracted from the stem and leaves of the Andrographis paniculata. The plant is grown for medicinal purposes in China and India and has traditionally been used as herbal medicine for common cold, fever and non-infectious diarrhea. Andrographolide has been shown to be effective against certain cancers and has also been shown to possess anticancer9-10, and hepatocyte-protective activities11.
14-Deoxy-11,12-didehydroandrographolide (DDAG) C20H28O4, is another diterpenoid isolated from A. paniculata18-19 . The structure of andrographolide and 14-deoxy-1 1,12-didehydroandrogapholide (DDA) is depicted In
Accordingly, a first aspect of the invention comprises a method of controlling inflammation in a lung cell comprising administering a dose of formula I.
wherein,
In one embodiment the cell is in vitro. In another embodiment the cell is in vivo and the formula I is administered to a patient in need of controlling an airway disorder.
In one embodiment formula I is Andrographolide. In another embodiment formula I is 14-deoxy-1 1,12-didehydroandrographolide.
In one embodiment controlling inflammation comprises controlling asthma. In another embodiment controlling inflammation comprises controlling allergenic effects. In another embodiment controlling inflammation comprises controlling chronic obstructive pulmonary disease (COPD).
Another aspect of the invention comprises a method of treating an airway disorder comprising administering a dose of formula I as defined above. In one embodiment formula I is Andrographolide for treating an airway disorder. In another embodiment formula I is 14-deoxy-1 1,12-didehydroandrographolide for treating an airway disorder. In one embodiment the airway disorder is an asthma exacerbation. In another embodiment the airway disorder is COPD. In another embodiment the method of treating the airway disorder may further comprising administering a corticosteroid.
Another aspect of the invention comprises a compound of formula I as defined above for use in treating an airway disorder. In one embodiment formula I is Andrographolide. In another embodiment formula I is 14-deoxy-1 1,12-didehydroandrographolide. In one embodiment the compound may be for treating the airway disorder of an asthma exacerbation. In another embodiment the compound may be for treating the airway disorder of COPD. In another embodiment the compound may further comprising administering a corticosteroid.
Another aspect of the invention comprises a Composition of a corticosteroid and formula I as described above. In one embodiment formula I of the composition may be Andrographolide. In another embodiment formula I of the composition may be 14-deoxy-1 1,12-didehydroandrographolide. In another embodiment the corticosteroid of the composition may be Dexamethasone, Budesonide, Fluticasone, Ciclesonide, or Beclomethasone Dipropionate.
[019]. In one embodiment the Composition may be for use in treating airway disorders such asthma or COPD.
The invention will be better understood by reference to the following description of several specific embodiments thereof as shown in the accompanying drawings in which:
Andrographis paniculata and/or andrographolide compounds were used to effectively reduced OVA-induced inflammatory cell recruitment into BAL fluid, IL-4, IL-5, IL-13 and eotaxin production, serum IgE synthesis, pulmonary eosinophilia, mucus hypersecretion and AHR in a mouse asthma model.
“Compounds” include known andrographolide compounds wherein the compound has the following structure:
wherein,
Suitable cyclic structures formed by OR2 and OR3 may be selected from-0-(CR7R8)m-O-where R7 and R8 may be same or different and independently represent hydrogen, unsubstituted or substituted groups selected from (C1-C6) alkyl such as methyl, ethyl, n-propyl and the like; aryl group such as phenyl, naphthyl and the like, the aryl group may be substituted; heteroaryl group such as pyridyl, furyl, thiophenyl, pyrrolyl and the like; the heteroaryl group may be substituted or R7 and R8 together represent ‘C=0’; m represents an integer 1 or 2. The substituents on R7 and R8 include hydroxy, halogen such as fluorine, chlorine, bromine and the like; nitro, cyano or amino groups.
The substituents on R2 may be selected from cyano, hydroxy, nitro, thio, halogen atom such as fluorine, chlorine, bromine and the like; substituted or unsubstituted groups selected from linear or branched (C1-C8) alkyl group such as methyl, ethyl, n-propyl, iso-propyl and the like; amino, mono or disubstituted amino group; alkanoyl group such as ethanoyl, propanoyl, butanoyl and the like; thio (C1-C8) alkyl such as thiomethyl, thioethyl, thiopropyl and the like; (C1-C6) alkoxy group such as methoxy, ethoxy, propyloxy, butyloxy and the like; aroyl group such as benzoyl and the like; acyloxy group such as acetyloxy, propanoyloxy, butanoyloxy and the like; aryl group such as phenyl, naphthyl and the like, the aryl group may be mono or disubstituted; heteroaryl group such as pyridyl, furyl, thienyl and the like; acylamino groups such as CH3CONH, C2H5CONH, C3H7CONH, C4H9CONH and C6H5CONH; aralkylamino group such as C6H5CH2NH, C6H5CH2CH2NH, C6H5CH2NCH3 and the like; alkoxycarbonylamino group such as C4H9OCONH, C2H5OCONH, CH3OCONH and the like; aryloxycarbonylamino group such as C6H50CONH, C6H5OCONCH3, C6H5OCONC2H5, C6H4 (CH3) OCONH, C6H4 (OCH3) OCONH and the like; aralkoxycarbonylamino group such as C6H5CH2OCONH, C6H5CH2CH2OCONH, C6H5CH2OCON (CH3), C6H5CH2OCON (C2H5), C6H4 (CH3) CH2OCONH, C6H4 (OCH3) CH2OCONH and the like; (C1-C8) alkylthio group such as methylthio, ethylthio, propylthio and the like; heteroarylthio group such as pyridylthio, furylthio, thiophenylthio, benzothiazolethio, purinethio, benzimidazolethio, pyrimidinethio and the like; acylthio group such as acetylthio, propanoylthio, butanoylthio and the like; aralkylthio group such asbenzylthio, phenylethylthio, phenylpropylthio and the like; arylthio group such as phenylthio, napthylthio and the like; (C1-C8) alkylseleno such as methylseleno, ethylseleno, propylseleno, iso-propylseleno and the like; acylseleno such as acetylseleno, propionylseleno and the like; aralkylseleno such as benzylseleno, phenylethylseleno, phenylpropylseleno and the like; arylseleno such as phenylseleno, napthylseleno and the like or COOR, where R represents hydrogen or (C1-C6) alkyl groups. The substituents are selected from halogen, hydroxy, nitro, cyano, amino, (C1-C6) alkyl, aryl or (C1-C6) alkoxy groups.
When the groups R2 represent disubstituted aryl, the two substituents on the adjacent carbon atoms form a linking group such as-X—CH2—Y—, —X—CH2—CH2—Y—, where X and Y may be same or different and independently represent O, NH, S or CH2 When the groups represented by R2 are multi substituted, the substituents present on the two adjacent carbons may form a linking group X— (CR9R10)n
[026]. Pharmaceutically acceptable salts forming part of this invention include salts derived from inorganic bases such as Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; salts of organic bases such as N, N′-diacetylethylenediamine, betaine, caffeine, 2-diethylamino ethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrab amine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N, N′-diphenylethylenediamine, N, N′-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metfonnin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine, and the like; chiral bases like alkylphenylamine, glycinol, phenyl glycinol and the like, salts of natural amino acids such as glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, omithine, lysine, arginin, serine, threonine, phenylalanine; unnatural amino acids such as D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl, ammonium or substituted ammonium salts and aluminum salts.
Salts may include acid addition salts where appropriate which are, sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, ketoglutarates and the like.
Pharmaceutically acceptable solvates may be hydrates or comprising other solvents of crystallization such as alcohols.
Particularly useful compounds of the present invention include: 3, 1 9-Diacetyl-12-(N-benzylamino)-14-deoxy andrographolide; 3,19-Diacetyl-12α-(N-benzylamino)-14-deoxy andrographolide; 3,19-Diacetyl-12 β-(N-benzylamino)-14-deoxy andrographolide; 14-Deoxy-12-(O-methylphenylglycino)-3, 19-O-(1-phenylethylidene) andrographolide; 14-Deoxy-12α-(O-methylphenylglycino)-3, 19-0-(I-phenylethylidene) andrographolide; 14-Deoxy-12β-(O-methylphenylglycino)-3, 19-0-(1-phenylethylidene) andrographolide; 3,19-Diacetyl-14-deoxy-12-(N-4-methoxybenzylamino) andrographolide; 3,19-Diacetyl-14-deoxy-12α-(N-4-methoxybenzylamino) andrographolide; 3,19-Diacetyl-14-deoxy-12β-(N-4-methoxybenzylamino) andrographolide; 3,19-Diacetyl-12-(N-2-chlorobenzylamino)-14-deoxy andrographolide; 3,19-Diacetyl-12α-(N-2-chlorobenzylamino)-14-deoxy andrographolide; 3,19-Diacetyl-12β-(N-2-chlorobenzylamino)-14-deoxy andrographolide; 3,19-Diacetyl-14-deoxy-12-(O-methylprolino) andrographolide; 3,19-Diacetyl-14-deoxy-12α-(O-methylprolino) andrographolide; 3,19-Diacetyl-14-deoxy-12β-(O-methylprolino) andrographolide; 3,19-Diacetyl-14-deoxy-12-(O-methylphenylalanino) andrographolide; 3,19-Diacetyl-14-deoxy-12α-(O-methylphenylalanino) andrographolide; 3,19-Diacetyl-14-deoxy-12β-(O-methylphenylalanino) andrographolide; 3,19-Diacetyl-14-deoxy-12-(O-methyl-3-phenylisoserino) andrographolide; 3,19-Diacetyl-14-deoxy-12α-(O-methyl-3-phenylisosetino) andrographolide; 3,19-Diacetyl-14-deoxy-12β-(O-methyl-3-phenylisoserino) andrographolide; 3,19-Diacetyl-14-deoxy-12-(O-methylmethionino) andrographolide; 3,19-Diacetyl-14-deoxy-12α-(O-methylmethionino) andrographolide; 3,19-Diacetyl-14-deoxy-12β-(O-methylmethionino) andrographolide; 3,19-Diacetyl-14-deoxy-12-(O-methylphenylglycino) andrographolide; 3,19-Diacetyl-14-deoxy-12αa-(O-methylphenylglycino) andrographolide; 3,19-Diacetyl-14-deoxy-12β-(O-methylphenylglycino) andrographolide; 3,19-Diacetyl-14-deoxy-12-(O-methylalanino) andrographolide; 3,19-Diacetyl-14-deoxy-12α-(O-methylalanino) andrographolide; 3,19-Diacetyl-14-deoxy-12β-(O-methylalanino) andrographolide; 3,19-Diacetyl-14-deoxy-12-(O-methylglycino) andrographolide; 3,19-Diacetyl-14-deoxy-12α-(O-methylglycino) andrographolide; 3,19-Diacetyl-14-deoxy-12β-(O-methylglycino) andrographolide; 3,19-Diacetyl-14-deoxy-12-(O-methylselenomethionino) andrographolide; 3,19-Diacetyl-14-deoxy-12α-(O-methylselenomethionino) andrographolide; 3,19-Diacetyl-14-deoxy-12β-(O-methylselenomethionino) andrographolide; 3,19-Diacetyl-14-deoxy-12-(N-imidazolyl) andrographolide; 3,19-Diacetyl-14-deoxy-12α-(N-imidazolyl) andrographolide; 3,19-Diacetyl-14-deoxy-12β-(N-imidazolyl) andrographolide; 3,19-Diacetyl-14-deoxy-12-(N-methylpiperazino) andrographolide; 3,19-Diacetyl-14-deoxy-12α-(N-methylpiperazino) andrographolide; 3,19-Diacetyl-14-deoxy-12β(N-methylpiperazino) andrographolide; 3,19-Diacetyl-14-deoxy-12-morpholino andrographolide; 3,19-Diacetyl-14-deoxy-12α-morpholino andrographolide; 3,19-Diacetyl-14-deoxy-12β-morpholino andrographolide, 3,19-Diacetyl-12-(N-acetylpiperazino)-14-deoxy andrographolide; 3,19-Diacetyl-12α-(N-acetylpiperazino)-14-deoxy andrographolide; 3,19-Diacetyl-12p-(N-acetylpiperazino)-14-deoxy andrographolide; 12-(N-Benzylamino)-14-deoxy andrographolide; 12α-(N-Benzylamino)-14-deoxy andrographolide; 12β-(N-Benzylamino)-14-deoxy andrographolide; 14-Deoxy-12-(O-methylphenylglycino) andrographolide; 14-Deoxy-12α-(O-methylphenylglycino) andrographolide; 14-Deoxy-12β-(O-methylphenylglycino) andrographolide; 14-Deoxy-3, 19-0-isopropylidene-12-(methylphenylalanino) andrographolide; 14-Deoxy-3,19-0-isopropylidene-12α-(methylphenylalanino) andrographolide; 14-Deoxy-3,19-0-isopropylidene-12β(methylphenylalanino) andrographolide; 12-(N-Benzylamino)-14-deoxy-3, 19-O-(1-phenylethylidene) andrographolide; 12α-(N-Benzylamino)-14-deoxy-3, 19-O-(1-phenylethylidene) andrographolide; 12β-(N-Benzylamino)-14-deoxy-3, 19-0-(1-phenylethylidene) andrographolide; 14-Deoxy-12-(O-methylphenylalanino)-3, 19-0-(1-phenylethylidene) andrographolide; 14-Deoxy-12α-(O-methlphenylalanino)-3, 19-O-(1-phenyletliylidene) andrographolide; 14-Deoxy-12β-(O-methylphenylalanino)-3, 19-O-(1-phenylethylidene) andrographolide; 14-Deoxy-12-(O-methylprolino)-3, 19-0-(1-phenylethylidene) andrographolide; 14-Deoxy-12α-(O-methylprolino)-3, 19-0-(1-phenylethylidene) andrographolide; 14-Deoxy-12β-(O-methylprolino)-3, 19-O-(1-phenylethylidene) andrographolide; 3, 19-O-B enzylidene-12-(N-benzylamino)-14-deoxy andrographolide; 3,19-O-Benzylidene-12αa-(N-benzylamino)-14-deoxy andrographolide; 3,19-0-Benzylidene-12β-(N-benzylamino)-14-deoxy andrographolide; 3,19-Diacetyl-14-deoxy-8, 17-epoxy-12-(O-methylmethionino) andrographolide; 3,19-Diacetyl-14-deoxy-8, 17-epoxy-12α-(O-methylmethionino) andrographolide; 3,19-Diacetyl-14-deoxy-8, 17-epoxy-12β-(O-methylmethionino) androgapholide; 3,19-Diacetyl-14-deoxy-8, 17-epoxy-12-(O-methylphenylglycino) andrographolide; 3,19-Diacetyl-14-deoxy-8, 17-epoxy-12α-(O-methylphenylglycino) andrographolide; 3,19-Diacetyl-14-deoxy-8, 17-epoxy-12β-(O-methylphenylglycino) andrographolide; 3,19-Diacetyl-14-deoxy-12-(N-1, 2, 4-triazolyl) andrographolide; 3,19-Diacetyl-14-deoxy-12α-(N-1, 2,4-triazolyl) andrographolide; 3,19-Diacetyl-14-deoxy-12β(N-1,2,4-triazolyl) andrographolide; 14-Deoxy-12-(2, 3-dimethylanilino) andrographolide; 14-Deoxy-12α-(2, 3-dimethylanilino) andrographolide; 14-Deoxy-12β-(2, 3-dimethylanilino) andrographolide; 3,19-Diacetyl-14-deoxy-12-(4-methoxy-2-methylanilino) andrographolide; 3,19-Diacetyl-14-deoxy-12α-(4-methoxy-2-methylanilino) andrographolide; 3,19-Diacetyl-14-deoxy-12β-(4-methoxy-2-inethylanilino) andrographolide; 3,19-Diacetyl-14-deoxy-12-(4-hydroxy-2-methylanilino) andrographolide; 3,19-Diacetyl-14-deoxy-12α-(4-hydroxy-2-methylanilino) andrographolide; 3,19-Diacetyl-14-deoxy-12-(4-hydroxy-2-methylanilino) andrographolide; 3,19-Diacetyl-14-deoxy-12-(2-mercaptoanilino) andrographolide; 3,19-Diacetyl-14-deoxy-12α-(2-mercaptoanilino) andrographolide; 3,19-Diacetyl-14-deoxy-12β-(2-mercaptoanilino) andrographolide; 3,19-Diacetyl-14-deoxy-12-(3, 4-dimethoxyanilino) andrographolide; 3,19-Diacetyl-14-deoxy-12α-(3, 4-dimethoxyanilino) andrographolide; 3,1 9-Diacetyl-14-deoxy-12β-(3, 4-dimethoxyanilino) andrographolide; 3,19-Diacetyl-12-anilino-14-deoxy andrographolide; 3,19-Diacetyl-12α-anilino-14-deoxy andrographolide; 3,1 9-Diacetyl-12β-anilino-14-deoxy andrographolide; 3,19-Diacetyl-14-deoxy-12-(2, 3-dimethylanilino) andrographolide; 3, 19-Diacetyl-14-deoxy-12α-(2, 3-dimethylanilino) andrographolide; 3,19-Diacetyl-14-deoxy-12β-(2, 3-dimethylanilino) andrographolide; 3,19-Diacetyl-14-deoxy-12-(2-methyl-4-methylsulfonateanilino) andrographolide; 3,19-Diacetyl-14-deoxy-12α-(2-methyl-4-methylsulfonateanilino) andrographolide; 3,19-Diacetyl-14-deoxy-12β-(2-methyl-4-methylsulfonateanilino) andrographolide; 3,19-Diacetyl-14-deoxy-12-(N-tetrazolylamino) andrographolide; 3,19-Diacetyl-14-deoxy-12α-(N-tetrazolylamino) andrographolide; 3,19-Diacetyl-14-deoxy-12β-(N-tetrazolylamino) andrographolide; 14-Deoxy-12-(3, 4-dimethoxyanilino) andrographolide; 14-Deoxy-12α-(3, 4-dimethoxyanilino) andrographolide; 14-Deoxy-12β-(3, 4-dimethoxyanilino) androgapholide; 14-Deoxy-3, 19-O-isopropylidene-12-(2, 3-dimethylanilino) andrographolide; 14-Deoxy-3, 19-O-isopropylidene-12α-(2, 3-dimethylanilino) andrographolide; 14-Deoxy-3, 19-0-isopropylidene-12β-(2, 3-dimethylanilino) andrographolide; 14-Deoxy-12-(2-methylanilino)-3, 19-0-(1-phenylethylidene) andrographolide; 14-Deoxy-12α-(2-methylanilino)-3, 19-0-(1-phenylethylidene) andrographolide; 14-Deoxy-12β-(2-methylanilino)-3, 19-O-(1-phenylethylidene) andrographolide; 3,19-O-Benzylidene-14-deoxy-12-(2, 3-dimethylanilino) andrographolide; 3,19-0-Benzylidene-14-deoxy-12α-(2, 3-dimethylanilino) andrographolide; 3,19-O-Benzylidene-14-deoxy-12β-(2,3-dimethylanilino) andrographolide; 3,19-Diacetyl-12-anilino-14-deoxy-8,17-epoxy andrographolide; 3,19-Diacetyl-12α-anilino-14-deoxy-8, 17-epoxy andrographolide; 3,19-Diacetyl-12β-anilino-14-deoxy-8, 17-epoxy andrographolide; 3,19-Diacetyl-14-deoxy-8, 17-epoxy-12-(2, 3-dimethylanilino) andrographolide; 3,19-Diacetyl-14-deoxy-8, 17-epoxy-12α-(2,3-dimethylanilino) andrographolide; 3,19-Diacetyl-14-deoxy-8, 17-epoxy-12β-(2, 3-dimethylanilino) andrographolide; 14-Deoxy-12-(N1-uracil) andrographolide; 14-Deoxy-12α-(N1-uracil) andrographolide; 14-Deoxy-12β-(N1-uracil) andrographolide; 3,19-Diacetyl-14-deoxy-12-[N-(1, 2-dihydro-2-pyrimidinone) amino]-1-andrographolide; 3,19-Diacetyl-14-deoxy-12α-[N-(1,2-dihydro-2-pyrimidinone) amino]-1-andrographolide; 3, 19-Diacetyl-14-deoxy-12β-[N-(1, 2-dihydro-2-pyrimidinone) amino]-1-andrographolide; 3,19-Diacetyl-14-deoxy-12-(N1-uracil) andrographolide; 3,19-Diacetyl-14-deoxy-12α-(N1-uracil) andrographolide; 3,19-Diacetyl-14-deoxy-12β-(N1-uracil) andrographolide; 3, 19-Diacetyl-1 4-deoxy-12-[N1(5-chlorouracil)] andrographolide; 3, 19-Diacetyl-14-deoxy-12β-[N1-(5-chlorouracil)]andrographolide; 3,19-Diacetyl-14-deoxy-12β-[N-(5-chlorouracil)] andrographolide; 3, 19-Diacetyl-14-deoxy-12-[N1-(5-bromouracil)] andrographolide; 3,19-Diacetyl-1 4-deoxy-12α-[N1-(5-bromouracil) Jandrographolide; 3,19-Diacetyl-14-deoxy-12β-[N1-(5-bromouracil)] andrographolide; 3,19-Diacetyl-14-deoxy-12-[N1-(5-fluorouracil] andrographolide; 3,19-Diacetyl-14-deoxy-12α-[N1-(5-fluorouracil] andrographolide; 3,19-Diacetyl-1 4-deoxy-1 2β-[N-(5-fluorouracil)] andrographolide; 3, 19-Diacetyl-1 4-deoxy-12-[N1-(5-iodouracil)] andrographolide; 3,19-Diacetyl-14-deoxy-12α-(5-iodouracil)] andrographolide; 3,19-Diacetyl-14-deoxy-12β-[N1-(5-iodouracil)] andrographolide;; 14-Deoxy-12-[N-(1, 2-dihydro-2-pyrimidinone) amino] andrographolide; 14-Deoxy-12α-[N-(1, 2-dihydro-2-pyrimidinone) amino] andrographolide; 14-Deoxy-12β-[N-(1, 2-dihydro-2-pyrimidinone) amino] andrographolide; 14-Deoxy-12-[NI-(5-fluorouracil)] andrographolidep; 14-Deoxy-12α-[N-(5-fluorouracil)] andrographolide; 14-Deoxy-12β-[N1-(5-fluorouracil)] andrographolide; 14-Deoxy-12-[N1-(5-bromouracil)] andrographolide; 14-Deoxy-12α-[N1-(5-bromouracil)] andrographolide; 14-Deoxy-12β-[N1-(S-bromouracil)] andrographolide; 14-Deoxy-12-[N1-(5-iodouracil)] andrographolide; 14-Deoxy-12α-[N1-(5-iodouracil)] andrographolide; 14-Deoxy-12β-[N1-(5-iodouracil)] andrographolide; 14-Deoxy-8,17-epoxy-12-phenylthio andrographolide; 14-Deoxy-8, 17-epoxy-12α-phenylthio andrographolide; 14-Deoxy-8, 17-epoxy-12β-phenylthio andrographolide; 3,19-Diacetyl-14-deoxy-12-phenylseleno andrographolide; 3,19-Diacetyl-14-deoxy-12α-phenylseleno andrographolide; 3,19-Diacetyl-14-deoxy-12β-phenylseleno andrographolide; 12-(C-Benzoylmethyl)-14-deoxy-13, 19-O-(1-phenylethylidene) andrographolide; 12α-(C-Benzoylmethyl)-14-deoxy-13, 19-O-(1-phenylethylidene) andrographolide; 12β-(C-Benzoylmethyl)-14-deoxy-13, 19-O-(1-phenylethylidene) andrographolide, 14-Deoxy-3,19-O-isopropylidene-12-ethylthio andrographolide; 14-Deoxy-3,19-O-isopropylidene-12α-ethylthio andrographolide; 14-Deoxy-3,19-0-isopropylidene-12β-ethylthio andrographolide; 3,19-Diacetyl-14-deoxy-12-phenylthio andrographolide; 3,19-Diacetyl-14-deoxy-12α-phenylthio andrographolide; 3,19-Diacetyl-14-deoxy-12β-phenylthio andrographolide; 3,19-Diacetyl-14-deoxy-12-acetylthio andrographolide; 3,19-Diacetyl-14-deoxy-12α-acetylthio andrographolide; 3,19-Diacetyl-14-deoxy-12β-acetylthio andrographolide; 3,19-Diacetyl-14-deoxy-12-ethylthio andrographolide; 3,19-Diacetyl-14-deoxy-12α-ethylthio andrographolide; 3,19-Diacetyl-14-deoxy-12β-ethylthio andrographolide; 3,19-Diacetyl-12-benzyl-14-deoxy andrographolide; 3,19-Diacetyl-12α-benzyl-14-deoxy andrographolide; 3,19-Diacetyl-12β-benzyl-14-deoxy andrographolide; 3,19-Diacetyl-14-deoxy-12-(1, 1′-diethyl dicarboxylate methyl) andrographolide; 3,1 9-Diacetyl-14-deoxy-12α-(1, 1′-diethyl dicarboxylate methyl) andrographolide; 3,19-Diacetyl-14-deoxy-12β-(1, 1′-diethyl dicarboxylate methyl) andrographolide; 14-Deoxy-12-phenylthio andrographolide; 14-Deoxy-12α-phenylthio andrographolide; 14-Deoxy-12β-phenylthio androgapholide; 14-Deoxy-12-ethylthio andrographolide; 14-Deoxy-12α-ethylthio andrographolide; 14-Deoxy-12β-ethylthio andrographolide; 14-Deoxy-12-phenylseleno andrographolide; 14-Deoxy-12α-phenylseleno andrographolide; 14-Deoxy-12β-phenylseleno andrographolide; 14-Deoxy-3, 19-O-isopropylidene-12-phenylthio andrographolide; 14-Deoxy-3,19-O-isopropylidene-12α-phenylthio andrographolide; 14-Deoxy-3,19-O-isopropylidene-12β--phenylthio andrographolide; 14-Deoxy-3,19-O-(1-phenylethylidene)-12-phenylthio andrographolide; 14-Deoxy-3,19-O-(1-phenylethylidene)-12α-phenylthio andrographolide; 14-Deoxy-3, 19-O-(1-phenylethylidene)-12β-phenylthio andrographolide; 14-Deoxy-3, 19-O-(1-phenylethylidene)-12-ethylthio andrographolide; 14-Deoxy-3,19-O-(1-phenylethylidene)-12α-ethylthio andrographolide; 14-Deoxy-3,19-O-(1-phenylethylidene)-12β-ethylthio andrographolide; 3,19-O-Benzylidene-14-deoxy-12-phenylthio andrographolide; 3, 19-O-Benzylidene-14-deoxy-12α-phenylthio andrographolide; 3,19-O-Benzylidene-14-deoxy-12β-phenylthio andrographolide; 3,19-Diacetyl-14-deoxy-8, 17-epoxy-12-phenylthio andrographolide; 3,19-Diacetyl-14-deoxy-8, 17-epoxy-12α-phenylthio andrographolide; 3,19-Diacetyl-14-deoxy-8, 17-epoxy-12β-phenylthio andrographolide; 12-Cimmamoyloxy-14-deoxy andrographolide; 12α-Cinnamoyloxy-14-deoxy andrographolide; 12β-Cinnamoyloxy-14-deoxy andrographolide; 12-Cinnamoyloxy-14-deoxy-8, 17-epoxy andrographolide; 12α-Cinnamoyloxy-14-deoxy-8, 17-epoxy andrographolide; 12β-Cinnamoyloxy-14-deoxy-8, 17-epoxy andrographolide; 14-Deoxy-12-hydroxy andrographolide; 14-Deoxy-12α-hydroxy andrographolide; 14-Deoxy-12β-hydroxy andrographolide; 12-Acetoxy-3,19-diacetyl-14-deoxy andrographolide; 12α-Acetoxy-3,19-diacetyl-14-deoxy andrographolide; 12β-Acetoxy-3, 19-diacetyl-14-deoxy andrographolide; 3,19-Diacetyl-14-deoxy-12-methoxy andrographolide; 3,19-Diacetyl-14-deoxy-12α-methoxy andrographolide; 3, 19-Diacetyl-14-deoxy-12β-methoxy andrographolide; 3,19-Diacetyl-14-deoxy-12-(2-acetoxy-3-N-acetylamino-3-phenylpropionyloxy) andrographolide; 3,19-Diacetyl-14-deoxy-12α-(2-acetoxy-3 -N-acetylamino-3-phenylpropionyloxy) andrographolide; 3,19-Diacetyl-14-deoxy-12β-(2-acetoxy-3-N-acetylamino-3-phenylpropionyloxy) andrographolide; 12-(N-Boc glycinyloxy)-14-deoxy-8, 17-epoxy-3, 19-dipropionyl andrographolide; 12α-(N-Boc glycinyloxy)-14-deoxy-8,17-epoxy-3,19-dipropionylandrographolide; 12β-(N-Boc glycinyloxy)-14-deoxy-8, 17-epoxy-3,19-dipropionyl andrographolide; 3,19-Diacetyl-14-deoxy-12-mercaptobenzothiazolyl andrographolide; 3,19-Diacetyl-14-deoxy-12α-mercaptobenzothiazolyl andrographolide; 3,19-Diacetyl-14-deoxy-12β-mercaptobenzothiazolyl andrographolide; 3,19-Diacetyl-12-(N, N-benzylchloroacetyl) amino-14-deoxy-12-andrographolide; 3,19-Diacetyl-12α-(N, N-benzylchloroacetyl) amino-14-deoxy-12-andrographolide and 3,19-Diacetyl-12β-(N, N-benzylchloroacetyl) amino-14-deoxy-12-andrographolide.
The compounds of the invention can be made by isolation from a plant Andrographis paniculata (Burm. f.) Nees, (Acanthaceae). Alternatively the compound may be synthesised using methods known in the art.
“Treatment” and “treat” and synonyms thereof refer to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an airway disorder. An airway disorder may include asthma, an asthma exacerbation, chronic obstructive pulmonary disease (COPD) and other airway disorders known to those skilled in the art.
As used herein a “therapeutically effective amount” of a compound will be an amount of active agent that is capable of treating, preventing or at least slowing down (lessening) an airway disorder. Dosages and administration of an antagonist of the invention in a pharmaceutical composition may be determined by one of ordinary skill in the art of clinical pharmacology or pharmacokinetics. An effective amount of the compound or composition to be employed therapeutically will depend, for example, upon the therapeutic objectives, the route of administration, and the condition of the mammal. Accordingly, it will be necessary for the therapist to titer the dosage and modify the route of administration as required to obtain the optimal therapeutic effect. A typical daily dosage might range from about 10 ng/kg to up to 100 mg/kg of the mammal's body weight or more per day, preferably about 1 μmg/kg/day to 10 mg/kg/day.
“Subject” for the purposes of the present invention includes humans and other animals, particularly mammals. Thus the methods are applicable to both human therapy and veterinary applications. In certain embodiments the subject is a mammal, and in a preferred embodiment the subject is human.
“Therapeutically effective amount” is an amount of a compound of the invention, that when administered to a patient, ameliorates a symptom of the disease. The amount of a compound of the invention which constitutes a “therapeutically effective amount” will vary depending on the compound, the disease state and its severity, the age and weight of the patient to be treated, and the like. The therapeutically effective amount can be determined routinely by one of ordinary skill in the art having regard to their knowledge and to this disclosure.
Compounds produced according to the invention can be administered for the treatment of airway disorders in the form of pharmaceutical compositions.
Thus, the present invention also relates to compositions including pharmaceutical compositions comprising a therapeutically effective amount of a compound of the invention. As used herein a compound will be therapeutically effective if it is able to affect the measured parameters of airway inflammation.
In a preferred embodiment the compounds and compositions are adapted to be administered to the lungs directly through the airways by inhalation. Compositions for administration by inhalation may take the form of inhalable powder compositions or liquid or powder sprays, and can be administrated in standard form using powder inhaler devices or aerosol dispensing devices. Such devices are well known. For administration by inhalation, the powdered formulations typically comprise the active compound together with an inert solid powdered diluent such as lactose or starch. Inhalable dry powder compositions may be presented in capsules and cartridges of gelatin or a like material, or blisters of laminated aluminium foil for use in an inhaler or insufflator. Each capsule or cartridge may generally contain between 20 pg-10 mg of the active compound. Alternatively, the compound of the invention may be presented without excipients.
The inhalable compositions may be packaged for unit dose or multi-dose delivery. For example, the compositions can be packaged for multi-dose delivery in a manner analogous to that described in GB 2242134, U.S. Pat. No. 6,632,666, U.S. Pat. No. 5,860,419, U.S. Pat. No. 5,873,360 and U.S. Pat. No. 5,590,645 (all illustrating the “Diskus” device), or GB2178965, GB2129691, GB2169265, U.S. Pat. No. 4,778,054, U.S. Pat. No. 4,811,731 and U.S. Pat. No. 5,035,237 (which illustrate the “Diskhaler” device), or EP 69715 (“Turbuhaler” device), or GB 2064336 and U.S. Pat. No. 4,353,556 (“Rotahaler” device).
Spray compositions for topical delivery to the lung by inhalation may be formulated as aqueous solutions or suspensions or as aerosols delivered from pressurised packs, such as a metered dose inhaler (MDI), with the use of a suitable liquefied propellant. The medication in pressurized MDI is most commonly stored in solution in a pressurized canister that contains a propellant, although it may also be a suspension.
Aerosol compositions suitable for inhalation can be presented either as suspensions or as solutions and typically contain the active compound and a suitable propellant such as a fluorocarbon or hydrogen-containing chlorofluorocarbon or mixtures thereof, particularly hydrofluoroalkanes such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, and especially 1,1, 1, 2-tetrafluoroethane, 1,1, 1,2, 3,3, 3-heptafluoro-n-propane and mixtures thereof
The aerosol composition may optionally contain additional excipients typically associated with such compositions, for example surfactants such as oleic acid or lecithin and cosolvents such as ethanol. Pressurised formulations will generally be contained within a canister (for example an aluminium canister) closed with a metering valve and fitted into an actuator provided with a mouthpiece.
Medicaments for administration by inhalation desirably have a controlled particle size. The optimum particle size for inhalation into the bronchial system is usually 1-10 μm, preferably 2-5 μm. Particles having a size above 20 μm are generally too large when inhaled to reach the small airways. To achieve these particle sizes the particles of the active ingredient may be subjected to a size reducing process such as micronisation. The desired size fraction may be separated out by air classification or sieving. Preferably, the particles will be crystalline. When an excipient such as lactose is employed, typically the particle size of the excipient will be much greater than the particle size of the active ingredient.
Intranasal sprays may be formulated with aqueous or non-aqueous vehicles with the addition of agents such as thickening agents, buffer salts or acid or alkali to adjust the pH, isotonic adjusting agents or anti-oxidants.
Solutions for inhalation by nebulisation may be formulated with an aqueous vehicle with the addition of agents such as acid or alkali, buffer salts, isotonic adjusting agents or antimicrobial agents. They may be sterilised by filtration or heating in an autoclave, or presented as a non-sterile product. Nebulizers supply the aerosol as a mist created from an aqueous formulation.
In one particular embodiment the composition is administered from a dry powder inhaler.
In another embodiment, the composition is administered by an aerosol dispensing device, preferably in conjunction with an inhalation chamber such as the “Volumatic” (RTM) inhalation chamber.
Pharmaceutical forms of the invention suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions and or one or more carrier. Alternatively, injectable solutions may be delivered encapsulated in liposomes to assist their transport across cell membrane. The composition must be stable under the conditions of manufacture and storage and must be preserved against the contaminating/destructive action of microorganisms such as, for example, bacteria and fungi.
The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as, for example, lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Preventing the action of microorganisms in the compositions of the invention is achieved by adding antibacterial and/or antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
Sterile inhalable or injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with several of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile inhalable or injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying, to yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.
When the active ingredients, in particular small molecules contemplated within the scope of the invention, are suitably protected they may be orally administered, for example, with an inert diluent or with an edible carrier, or it may be enclosed in hard or soft shell gelatin capsule, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet. For oral therapeutic administration, the active compound may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 1% by weight of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 5 to about 80% of the weight of the unit. The amount of active compound in such therapeutically useful compositions in such that a suitable dosage will be obtained. Preferred compositions or preparations according to the present invention are prepared so that a dosage unit form contains between about 0.1 μg and 20 g of active compound.
The tablets, troches, pills, capsules and the like may also contain binding agents, such as, for example, gum, acacia, corn starch or gelatin. They may also contain an excipient, such as, for example, dicalcium phosphate. They may also contain a disintegrating agent such as, for example, corn starch, potato starch, alginic acid and the like. They may also contain a lubricant such as, for example, magnesium stearate. They may also contain a sweetening agent such a sucrose, lactose or saccharin. They may also contain a flavouring agent such as, for example, peppermint, oil of wintergreen, or cherry flavouring.
When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier.
Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparaben as preservatives, a dye and flavouring such as, for example, cherry or orange flavour. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compound(s) may be incorporated into sustained-release preparations and formulations.
To this extent the active ingredient may be held within a matrix which controls the release of the active agent. Preferably, the matrix comprises a substance selected from the group consisting of lipid, polyvinyl alcohol, polyvinyl acetate, polycaprolactone, poly(glycolic)acid, poly(lactic)acid, polycaprolactone, polylactic acid, polyanhydrides, polylactide-co-glycolides, polyamino acids, polyethylene oxide, acrylic terminated polyethylene oxide, polyamides, polyethylenes, polyacrylonitriles, polyphosphazenes, poly(ortho esters), sucrose acetate isobutyrate (SAIB), and combinations thereof and other polymers such as those disclosed in U.S. Pat. Nos. 6,667,371; 6,613,355; 6,596,296; 6,413,536; 5,968,543; 4,079,038; 4,093,709; 4,131,648; 4,138,344; 4,180,646; 4,304,767; 4,946,931, each of which is expressly incorporated by reference herein in its entirety. Preferably, the matrix sustainedly releases the drug.
Pharmaceutically acceptable carriers and/or diluents may also include any and all solvents, dispersion media, coatings, antibacterials and/or antifungals, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the therapeutic compositions is contemplated.
Supplementary active ingredients can also be incorporated into the compositions. Preferably those supplementary active ingredients are anti-inflammatory agents such as inhaled steroids, cysteinyl-leukotriene receptor antagonist and cromolyn and or bronchodilators such as (32 agonists and/or anticholinergics. Some inhaled steroids may include Dexamethasone, Budesonide (Pulmicort®), Fluticasone (Flovent®), Ciclesonide (Alvesco®), Beclomethasone Dipropionate (QVAR®) or others known in the art. β2 agonists may include salbutamol, albuterol, terbutaline, salmeterol, or formoterol. An anticholinergic may include Ipratropium.
It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active material for the treatment of disease in living subjects having a diseased condition in which bodily health is impaired as herein disclosed in detail.
The principal active ingredient is compounded for convenient and effective administration in effective amounts with a suitable pharmaceutically acceptable carrier in dosage unit form. A unit dosage form can, for example, contain the principal active compound in amounts ranging from 0.5 μg to about 2000 mg. Expressed in proportions, the active compound is generally present in from about 0.5 pg to about 2000 mg/ml of carrier. In the case of compositions containing supplementary active ingredients, the dosages are determined by reference to the usual dose and manner of administration of-the said ingredients.
The compound or the composition may be in the form of a treatment kit comprising the dosage unit forms and instructions for use.
Preferably Andrographolide or 14-deoxy-1 1,12-didehydroandrographolide (DDAG) may be able to replace or reduce the dosage of glucocorticoid either with DDAG alone or by combination therapy of DDAG and glucocorticoid in the treatment of asthma.
We propose the use of andrographolide compounds such as andrographolide and DDA (DDAG) to complement or to replace oral steroids during airway disorders such as asthma exacerbation.
We describe a Novel Anti-Inflammatory Role for Andrographolide in Asthma via Inhibition of The Nuclear Factor-κB Pathway. Persistent activation of nuclear factor (NF)-κB has been associated with the development of asthma. Andrographolide, the principal active component of a medicinal plant Andrographis paniculata, has been shown here to inhibit NF-κB activity. Andrographolide attenuates allergic asthma via inhibition of the NF-κB signaling pathway in BALB/c mice sensitized and challenged with OVA developed airway inflammation.
Andrographolide inhibited OVA-induced increases in total cell count, eosinophil count, and IL-4, IL-5 and IL-13 levels in bronchoalveolar lavage fluid, and reduced serum level of OVA-specific IgE. It attenuated OVA-induced lung tissue eosinophilia and airway mucus production, mRNA expression of E-selectin, chitinases, MucSac and inducible nitric oxide synthase in lung tissues, and airway hyperresponsiveness to methacholine. In human lung epithelial cells, andrographolide blocked TNF-α-induced phosphorylation of inhibitory κB (IκB) kinase-β (IKKβ), and downstream IκBαdegradation, p65 subunit of NF-κB phosphorylation, and p65 nuclear translocation and DNA-binding activity. Our findings implicate a potential therapeutic value of andrographolide in the treatment of asthma and it may act by inhibiting NF-κB pathway at the level of IKKβ activation.
We describe for the first time that DDAG effectively reduced OVA-induced inflammatory cell recruitment into BAL fluid, IL-4, IL-5, IL-13 and eotaxin production, serum IgE synthesis, pulmonary eosinophilia, mucus hypersecretion and AHR in a mouse asthma model potentially via inhibition of NF-κB activity. Moreover, at doses that do not show any anti-inflammatory effects when given alone, combination of low dose of DDAG and glucocorticoid treatment synergistically attenuated inflammation in mouse asthma model. These findings support a therapeutic value for DDAG in the treatment of asthma.
We propose to use andrographolide or 14-deoxy-11,12-didehydroandrograholide (DDA) for the treatment of asthma as a controller. In addition, 5-10% of the asthmatics are not well-controlled by current drug treatment and they require oral steroids during exacerbation. We propose to use andrographolide or DDA to complement oral steroids or replace oral steroid during asthma exacerbation.
A novel anti-Inflammatory role of andrographolide in treating asthma via Inhibition of the NF-κB pathway. In our mouse asthma model using ovalbumin as aeroallergen, we showed that andrographolide dose-dependently Inhibited ovalbumin-Induced cell Infiltration Into the airways obtained from bronchoalveolar lavage fluid and observed in formalin-fixed lungs as shown in
Andrographolide was able to suppress ovalbumln-Induced cytoklne production obtained from BAL fluid (
Furthermore, andrographolide was able to suppress ovalbumin-induced expression pro-inflammatory adhesion molecules and biomarkers (
Andrgrapholide reduced ovalbumin-induced eosinophil count in BAL fluid and it inhibited E-selectin and VCAM-1 staining in lung sections (
In addition, we have data showing DDAG (14-deoxy-1 1,12-didehydroandrographolide) anti-inflammatory effects in asthma.
DDAG dose-dependently inhibited ovalbumin-induced increases in total cell count, eosinophil count, and IL-4, IL-5 and IL-13 levels recovered in bronchoalveolar lavage fluid (BALF), and reduced serum level of ovalbumin-specific IgE. It attenuated ovalbumin-induced lung tissue eosinophilia and airway mucus production, mRNA expression of E-selectin, chitinases, COX-2, IL-17, IL-33 and Muc5ac in lung tissues, and airway hyper-responsiveness to methacholine. In normal human bronchial epithelial cells, DDAG blocked TNF-α-induced p65 nuclear translocation and DNA binding activity. Similarly, DDAG blocked p65 nuclear translocation and DNA-binding activity in the nuclear extracts from lung tissues of ovalbumin-challenged mice.
Additionally, low dose Dexamathasone combination synergistically inhibited BALF ovalbumin-induced total cell count, eosinophil count and IL-4, IL-5, IL-13 and even Eotaxin levels.
In the mouse asthma model using ovalbumin as aeroallergen, we showed that DDA dose-dependently inhibited ovalbumin-induced cell Infiltration into the airways obtained from bronchoalveolar lavage fluid
Several Inflammatory marker gene expression profiles are inhibited by DDA and the Inhibitory effects of DDA on airway hyper-responsiveness.
We propose the use of andrographolide and DDA as an anti-inflammatory agent for controlling asthma.
BALB/c mice sensitized and challenged with ovalbumin developed airway inflammation. Bronchoalveolar lavage fluid was assessed for total and differential cell counts, and cytokine and chemokine levels. Serum IgE levels were also determined. Lung tissues were examined for cell infiltration and mucus hypersecretion, and the expression of inflammatory biomarkers. Airway hyperresponsiveness was monitored by direct airway resistance analysis.
DDAG elicited a significant inhibition on p65 nuclear translocation and κB DNA-binding activity in OVA-challenged lungs in vivo and in normal human bronchial epithelial cells in vitro. Reduction in IL-4, IL-5, IL-13 and eotaxin in BAL fluids may be due to inhibition of NF-κB by DDAG in inflammatory and airway resident cells. Reduction in airway eosinophilia by DDAG may be due to decreased IL-13, eotaxin, RANTES and E-selectin expression, secondary to NF-κB inhibition.
Reduction in serum total and OVA-specific IgE by DDAG may be due to inhibitory effect on B cell activation via inhibition of NF-κB. Therefore, reduction in airway hyper-responsivness by DDAG was observed. Although DDAG is not as active as steroid, it demonstrate significant synergistic anti inflammatory effect when a low dose of DDA was use in combination with low dose of steroid.
BAL fluid was collected 24 hours after the last OVA or saline aerosol challenge, and total and differential cell counts were performed. OVA inhalation markedly increased total cell and eosinophil counts, but slightly yet significantly (P<0.05) increased macrophage, lymphocyte and neutrophil counts, as compared with saline aerosol control. DDAG (0.1, 0.5 and 1 mg/kg) drastically decreased the total cell and eosinophil counts in BAL fluid in a dose-dependent manner as compared with the DMSO vehicle control (
Lung tissue was also collected 24 hours after the last OVA or saline aerosol challenge. OVA aerosol challenge induced marked infiltration of inflammatory cells into the peribronchiolar and perivascular connective tissues as compared with saline aerosol challenge. DDAG (1 mg/kg) markedly diminished the eosinophil-rich leukocyte infiltration as compared with DMSO control (
OVA inhalation in sensitized mice caused a notable increase in IL-4, IL-5, IL-13 and eotaxin levels into BAL fluid as compared with saline aerosol control (
To further evaluate whether DDAG could modify an ongoing OVA-specific Th2 response in vivo, serum levels of total IgE, and OVA-specific IgE, IgG1 and IgG2a were determined using ELISA. Marked elevation in serum total IgE, OVA-specific IgE and OVA-specific IgG1 levels, but not OVA-specific IgG2a level, were observed in OVA-challenged mice as compared with saline-challenged mice (
To investigate the effect of DDAG on AHR in response to increasing concentrations of methacholine, we measured both RI and Cdyn in mechanically ventilated mice. RI is defined as the pressure driving respiration divided by flow. Cdyn refers to the distensibility of the lung and is defined as the change in volume of the lung produced by a change in pressure across the lung. OVA-challenged mice developed AHR which is typically reflected by high RI and low Cdyn (
DDAG Inhibits OVA-Induced Inflammatory Gene Expression and NO production in Allergic Airway Inflammation
OVA aerosol challenge markedly up-regulated lung mRNA levels of adhesion molecule E-selectin, which is pivotal for pulmonary recruitment of inflammatory cells like eosinophils and lymphoctyes; chitinase family members including acidic mammalian chitinase (AMCase), Ym1, Ym2 and YKL-40, which have recently been shown to play critical roles in airway inflammation and remodeling26-28; Muc5ac, which is essential for mucus hypersecretion29. IL-33 is known to recruit, activate and enhance Th2 T cell function30; IL-17 has been shown to induce the release of eotaxin from airway smooth muscle cells, and both IL-17 and IL-17F were able to induce the release of in flammatory mediators from human eosinophils in vitro31. Pretreatment with DDAG (1 mg/kg) demonstrated strong suppression of E-selectin, AMCase, Ym-2, YKL-40, Muc5ac, COX2, IL-17 and IL-33 in the allergic airways (
DDAG Inhibits OVA-Induced NF-KB Function in Allergic Airway Inflammation and TNF-α-induced NF-κB Activation in Normal Human Bronchial Epithelial Cells
To verify that the anti-inflammatory effects of DDAG in OVA-challenged mice were mediated by the inhibition of NF-KB, we examined nuclear translocation of p65 subunit of NF-κB and p65 DNA-binding activity in lung tissues obtained 24 hours after the last OVA or saline aerosol challenge. OVA challenge markedly raised the level of p65 subunit in the nuclear extract of the lung tissue and promoted nuclear p65 DNA-binding activity as compared with saline aerosol control (
To further explore anti-inflammatory mechanisms of action of DDAG in a relevant airway cell type, we studied the effects of DDAG on TNF-α-induced activation of NF-κB and cytokine mRNA expression in normal primary human bronchial epithelial cells. TNF-α plays a critical role in asthma32-33 and is a potent stimulator of human airway epithelial cells34. A sharp increase in nuclear p65 level and in p65 DNA-binding activity was observed (
Low dose of DDAG and Dexamethasone Synergistically Suppress OVA Induced Inflammatory Cell Recruitment and Reduces OVA-Induced BAL Fluid Th2 Cytokine Levels
To study the combinational effect of DDAG and Glucocorticoids in OVA-induced airway inflammation, BAL fluid was collected 24 hours after the last OVA or saline aerosol challenge, and total and differential cell counts were performed. The lowest dose of DDAG (0.1 mg/kg) in combination with low dose of Dexamethasone (0.05 mg/kg) drastically decreased the total cell and eosinophil counts in BAL fluid as compared with the OVA sensitize and challenge but treated mice as positive control (
Persistent NF-κB activation has been observed in allergic airway inflammation both in human and in animal models of asthma35-38. Antigen receptor activation in T and B lymphocytes and mast cells culminates in NF-κB activation39-40. In addition, TNF-α stimulation of airway epithelial cells triggers NF-icB-dependent gene expression34. Various therapeutic strategies targeted at the NF-κB signaling pathway such as NF-κB-specific decoy oligonucleotide41, p65-specific antisense oligonucleotide42 and IMO-selective small molecule inhibitor43 have demonstrated beneficial effects in experimental asthma models.
Our findings reveal a significant inhibition of p65 nuclear translocation and κB DNA binding activity by DDAG in OVA-challenged lungs in vivo. To be more specific, our immunoblotting analysis of TNF-α-stimulated normal human bronchial epithelial cells in vitro shows that andrographolide reduced nuclear translocation of p65, and diminished p65 κB oligonucleotide binding. Taken together, we have established that Andrographolide and DDAG, the principal active component of a medicinal plant Andrographis paniculata, can effectively suppress various aspects of OVA-induced Th2-mediated allergic airway inflammation in mice potentially via inhibition of NF-κB activity. As these compounds share the same basic structure as formula I (see FIGS. A and B) presumably other compounds containing the same basic structure as formula I will have a similar effect on airway inflammation.
Th2 cytokines play an essential role in the pathogenesis of the allergic airway inflammation1-2, and NF-κB is a critical transcription factor for Th2 cell differentiation44. IL-4, IL-5 and IL-13 can be produced by various lung resident cells such as bronchial epithelial cells, tissue mast cells and alveolar macrophages as well as infiltrated inflammatory cells such as lymphocytes and eosinophils.
Our present results show that DDAG significantly reduced the levels of IL-4, IL-5, IL-13 and eotaxin in BAL fluids from OVA-challenged mice. Similar findings were observed in OVA-challenged mice with disrupted NF-κB function via conditional knockout of IKKβ or transgenic IκBα mutant expression selectively in airway epithelium38,45. Consistently, expression of IL-33 which enhances the production of IL-5 and IL-13 by Th2 cells but not by Thl cells in vitro is drastically reduce by DDAG. In addition, repression of NF-κB signaling pathway has been shown to block IL-13-induced eotaxin production in cultured human airway smooth muscle cells43. Therefore, the observed reduction of IL-4, IL-5, IL-13 and eotaxin levels in BAL fluid from DDAG-treated mice may be due to inhibition of NF-κB activation in the inflammatory and airway resident cells. These data show that the anti-inflammatory effect of DDAG is at least in part mediated through a suppressive action on T lymphocytes.
Eosinophils play a central role in the pathogenesis of allergic inflammation 5,7. Our present findings showed that DDAG prevented inflammatory cell infiltration into the airways as shown by a significant drop in total cell counts and eosinophil and lymphocyte counts in BAL fluid, and in tissue eosinophilia in lung sections. Leukocyte transmigration into the airways is orchestrated by cytokines like IL-4, IL-5 and IL-13, and coordinated by specific chemokines like eotaxin and RANTES in combination with adhesion molecules such as VCAM-1 and E-selectin7,25. IL-13 is by far the most potent inducer of eotaxin expression in airway epithelial cells47. IL-17 has also been shown to induce Eotaxin from airway smooth muscle cell48. We have demonstrated that DDAG strongly suppressed E-selectin and IL-17 mRNA expression and eotaxin production in OVA-challenged lungs, and RANTES mRNA expression in TNF-α-stimulated normal human bronchial epithelial cells. These findings are likely to be due to DDAG-mediated NF-κB inhibition, as the genes for Eselectin, eotaxin and RANTES contain the κB site for NF-κB within their promoters49.
Taken together, the observed reduction in airway eosinophilia by andrographolide and DDAG may be a result of combined inhibitory effects on IL-13, eotaxin and RANTES production, and on E-selectin expression, secondary to inhibition of NF-κB activation. We have also demonstrated a dramatic reduction in airway mucus production in DDAG-treated mice as compared with DMSO control. Cumulative evidence indicates that IL-4, IL-5 and IL-13 play a critical role in goblet cell hyperplasia and mucin Muc5ac gene and protein expression in mice29,50. Interestingly, Muc5ac gene expression is dependent on the transcriptional activity of NF-κB29, 49, 51. We also observed a substantial drop in Muc5ac mRNA expression by andrographolide and DDAG in OVA-challenged lungs. Selective ablation of NF-κB function in airway epithelium has been shown to reduce OVA-induced mucus production in mice38, 45. As such, the marked decrease in mucus production in the lungs of Eotaxin-treated mice may be attributable to a significant reduction of IL-4, IL-5 and IL-13 levels, and a direct inhibitory action on NF-κB in airway epithelium.
Elevated serum IgE levels are a hallmark of the Th2 immune response. Our data showed that serum levels of total IgE and OVA-specific IgE were substantially reduced by andrographolide and DDAG in OVA-challenged mice. In addition, NF-κB plays a crucial role in B cell proliferation and development39,52, and IL-4 and IL-13 are important in directing B cell growth, differentiation and secretion of IgE3,6. The biological activities of IgE are mediated through its interaction with the FcεRI on mast cells and basophils. Cross-linking of FcεRI initiates multiple signaling cascades leading to NF-κB activation and production of lipid mediators, cytokines and chemokines4, 40. Therefore, the observed reduction in serum total IgE and OVA-specific IgE by andrographolide and DDAG in our asthma model may be contributed by its inhibitory effect on B cell activation via inhibition of NF-κB activation, and on IL-4- and IL-13-mediated class switching to IgE.
A family of chitinase proteins including AMCase, Ym1, Ym2 and YKL-40 has recently been found to be markedly elevated in allergic airway inflammation in human and in mouse asthma models26-28. They are mainly expressed in airway epithelium and alveolar macrophages. AMCase level is increased in a mouse asthma model and in asthmatic subjects in an IL-13-dependent manner26. When given intratracheally, IL-13 elevates Ym1 and Ym2 levels in BAL fluid from mice in vivo53. Besides, YKL-40 serum level correlates positively with asthma severity, airway remodeling and deterioration of pulmonary function in asthmatic subjects28. Overall, chitinases may play a role in airway inflammation and remodeling. Our data show that andrographolide markedly down-regulated AMCase, Ym2 and YKL-40 mRNA expression in the lungs of OVA-challenged mice. These may be a consequence of the major drop in IL-4 and IL-13 levels in the airways with andrographolide or DDAG treatment and may contribute to the diminished pulmonary eosinophilia.
It is believed that inflammatory mediators released during the allergic inflammation play a critical role in AHR development54. We report here that DDAG significantly inhibited OVA-induced AHR to increasing concentrations of methacholine. It has been established that IL-5 plays a critical role in AHR by mobilizing and activating esoinophils, leading to the release of pro-inflammatory products such as major basic protein and cysteinyl-leukotrienes which are closely associated with AHR5, 7. In addition, IL-4 and IL-13 have been shown to induce AHR in mouse asthma models in which cysteinyl-leukotrienes have been implicated in AHR6, 55-56. Moreover, IgE mediated mast cell activation may contribute to AHR by producing a wide array of inflammatory mediators and cytokines4,40. The increase in airway hyperresponsiveness in OVA challange mice may be due to the increased in degranulating mast cell counts found in the lung tissue as the mast cell mediators directly constrict smooth muscle cells and potentiate their constrictor response57. Thus, the observed reduction of AHR by DDAG may be associated with the reduction in Th2 cytokine production, tissue eosinophilia, serum IgE level and mast cell degranulation.
Corticosteroids may regulate gene expression in several ways. At clinical dosage, glucocorticoid receptors (GRs), after activation by corticosteroids, translocate to the nucleus and bind to coactivators of NF-κB and recruit histone deacetylase (HDAC)2 to reduce histone acetylation that leads to suppression of these activated inflammatory genes59. The main effect of glucocorticoids is to suppress inflammatory transcription factors activities.
Nuclear factor κB activation inhibition by compounds having formula I such as andrographolide or DDAG or the others described herein hold positive prospect in treating patients with glucocorticoid resistance.
[099]. As high dosage oral steroids for long periods is associated with severe side effects, steroid-sparing treatments have been sought after. Even though the anti-inflammatory activities that andrographolide or DDAG exert are less than corticosteroid and nonsteroidal drugs the ability of andrographolide or DDAG to reduce airway inflammation, airway hyperesponsiveness and reduce IgE level led to the speculation that andrographolide or DDAG might be used to control severe, poorly controlled bronchial asthma.
We also examined the therapeutic effect of DDAG and low dose of glucocorticoid in asthma mouse model. We report that DDAG and Steroid can significantly reduced inflammation even at the lowest dose of DDAG and low dose of Steroid combination. By comparing with DDAG alone or Dexamethasone alone, aside from IL-4, IL-5 and IL-13, the DDAG and Dexamethasone combination also significantly decrease the Eotaxin level. Eotaxin recruits eosinophils by inducing their chemotaxis. Thus, therapeutic use of DDAG in combination with a low dose steroid can reduce the dosage of corticosteroid needed for administration, thereby reducing the possible side effect cause by high dosage of glucocorticoid administration.
Female BALB/c mice (Interfauna, East Yorkshire, UK), were housed in appropriate cages (maximum 4 mice/cage) at the Animal Holding Unit (AHU), NUS. The temperature and humidity of the housing environment were maintained at approximately 22° C. and 55% respectively. Commercial mouse feed and water were provided ad libitum. The beddings were changed three times a week to ensure cleanliness of the living conditions. The handling of mice and the experiments carried out strictly followed the guidelines approved by the Institutional Animal Care and Use Committee (IACUC) of NUS, Singapore.
All mice were acclimatized for at least one week before sensitization. A sensitization mixture was prepared by dissolving 20 μg of OVA and 4 mg of Al(OH)3 in 0.1 ml of Saline. The murine asthma model was developed by sensitizing the mice with 0.1 ml of sensitization mixture on Day 0 and Day 14 using intraperitoneal (i.p.) injections.
The sensitized mice were subjected to airway challenge to produce both the control model as well as the asthma model. A challenge mix was prepared by dissolving 0.15 g OVA into 15 ml of saline solution. The mice were then challenged with aerosolized 1% OVA for 30 minutes on Day 22, 23, 24 to stimulate asthmatic response. A negative control for the asthma model was developed by performing saline challenge on several mice. In this case, 15 ml of saline was used as the challenge mix.
An ultrasonic nebulizer (Ultra-Neb™ 2000 from DeVilbiss Healthcare Inc, USA) was employed to perform the challenge process. The nebulizer aerosolized the challenge mix and pumped the aerosol mist (particle size<5 μm) into an adjacent aerosol chamber where the mice were placed. Mice inhaling aerosolized 1% OVA would be re-exposed to the antigen in the airway, generating an immune response in the airway that mimics asthma pathogenesis and thus creating an ideal model for asthma.
1000 grams of Andrographis paniculata aerial part (biomass) are covered with 3.2 liters of 70% ethanol at 65° for 3 hours in a static percolator. Then the percolate is recovered and the biomass is extracted 5 times again under the same conditions, but using 2.6 liters of solvent per extraction, so obtain approximately 15.2 liters of percolate. The combined percolates are filtered and concentrated by a rotary evaporator at 60° under reduced pressure. The extract is dried at 60° under reduced pressure for one night. This extract has a total dry residue of 90.9 g, the yield vs starting material being 10.1 w/w. The Andrographolide HPLC content is 22.38%. Alternatively the andrographolide or DDAG may be purchased commercially from Sigma, St. Louis, Mo.
Andrographolide or DDAG alone (0.1, 0.5, and 1 mg/kg; Sigma, St. Louis, Mo.) or vehicle (1% dimethyl sulfoxide [DMSO]) in 0.1 ml saline was given by intraperitoneal injections 2 hour before and 10 hours after each OVA aerosol challenge. Andrographolide or 14-deoxy-11,12-didehydroandrographolide (DDA) were prepared from stock. DMSO was used as a solvent to dissolve Andrographolide or DDA. A stock solution of 10 mg/ml was prepared and stored at −20° C. When used, the stock solution was thawed and diluted with Saline solution to form three different drug concentrations: 0.01 mg/ml, 0.05 mg/ml and 0.1 mg/ml. The preparation is shown in Table 1.
There were six treatment groups in this study as presented in Table 2. Group A (Saline) consisted of mice sensitized with OVA and challenged with Saline, that served as the negative control group. Group B (OVA) consisted of positive murine asthma model that were OVA-sensitized and OVA-challenged. Group C (DMSO) consisted of mice that were OVA-sensitized, OVA challenged and given intraperitoneal (i.p.) injections of 1% DMSO 2 hours before challenge. This group served as a vehicular control and a negative control for the drug.
Group D (0.1 mg/kg DDA) consisted of mice that were OVA-sensitized, OVA-challenged and given intraperitoneal (i.p.) injections of 0.1 mg/kg andrographolide or DDAG 0.1 mg/kg 2 h before challenge and 10 h later. Group E (0.5 mg/kg DDAG) consisted of mice that were OVA-sensitized, OVA-challenged and given intraperitoneal (i.p.) injections of 0.5 mg/kg andrographolide or 0.5 mg/kg DDAG 2 h before challenge and 10 h later. Group F (1.0 mg/kg andrographolide or 1.0 mg/kg DDAG) consisted of mice that were OVA-sensitized, OVA challenged and given intraperitoneal (i.p.) injections of 1.0 mg/kg DDA 2 h before challenge and 10 h later.
Bronchoalveolar lavage (BAL) was conducted on Day 25, 24 hours after the final OVA/saline challenge. Mice were anaesthetized by 0.3 ml i.p. injections of an anesthetic cocktail (ketamine: medetomidine: H2O=3:4:33, Parnell, Alexandria NSW, Australia & Pfizer, Auckland, New Zealand) with 27 G½ sterile needle (PrecisionGlide®). Mice were sacrificed by cervical dislocation 5 minutes after anesthetization. 25 G½ sterile needles (PrecisionGlide®) were used for blood extraction. When withdrawing the blood, the needles were pierced diagonally into the wall of the left ventricles, and the aspiration should be slow so that the blood flow did not collapse. Tracheotomy was then performed and a small transverse incision was made on the exposed trachea. Blunt needles (20 G), which were connected to 1 ml sterile syringes, were inserted into the trachea through this incision and 0.5 ml of ice-cold PBS (4° C.) was instilled thrice into the lungs (0.5 ml×3). About 1.2-1.4 ml of BAL fluid was retrieved from each mouse and was kept in −80° C. for subsequent experiments.
Blood collected from the hearts were allowed to clot for at least 4 h. Centrifugation at 3000 rpm for 5 min at 4° C. was then performed on all blood samples. The supernatant, which is the serum, was extracted carefully and stored at −80° C. The samples were kept for ELISA.
BAL fluid collected from the lungs of the mouse was centrifuged at 3000 rpm for 5 min at 4° C. The supernatant was collected and stored at −80° C. The pellet was resuspended in 200 μl of 0.875% NH4Cl (8.75 mg NH4Cl in 1 ml MilliQ water) and incubated for 5 minutes at room temperature to remove unwanted erythrocytes. The cell suspension was then centrifuged at 3000 rpm for 5 min at 4° C. The supernatant was discarded and the pellet containing inflammatory cells was resuspended in 200 μl of RPMI with 1% BSA (10 mg BSA in 1 ml RPMI). The total number of viable cells was enumerated using a haemocytometer (10 μl of 0.4% trypan blue: 10 μl of cell suspension), under a microscope at 200×magnification.
Following the total cell count, dilutions were performed on the BAL fluid collected with the RPMI/BSA solution (1×105 cells per 150 μl of RPMI/BSA). Cytocentrifugation was then carried out on all samples using a Cytospin centrifuge (Thermo Shandon, Pittsburgh, USA) at 600 g for 10 minutes to fix the cells on glass slides. Smears of the infiltrating inflammatory cells were allowed to air-dry and then stained using Liu staining (modified Wright staining). In Liu staining, cytospin slides were stained with 800 μl of Liu A for 30 seconds and then followed by 1600 μl of Liu B for 90 seconds. Slides were left to dry overnight and glass cover slips were mounted onto the stain. Differential cell count was then performed on a minimum of 500 cells under the microscope (1000×magnification) for each cytospin slide. Four types of inflammatory cells namely macrophages, eosinophils, neutrophils and lymphocytes were identified and their respective ratio was enumerated based on the staining outcome and distinctive morphological features. The absolute number of each inflammatory cell was calculated.
DDAG alone (0.1, 0.5, and 1 mg/kg; Sigma, St. Louis, Mo.) or vehicle (2% dimethyl sulfoxide [DMSO]) in 0.1 ml saline was given by intraperitoneal injections 2 hour before and 10 hours after each OVA aerosol challenge. In the combinational experiments, DDAG (0.1 mg/kg) in combination with Dexamethasone (0.05 mg/kg) was given intraperitoneally. In both experimental setting, saline aerosol was used as a negative control. Animal experiments were performed according to the Institutional guidelines for Animal Care and Use Committee of the National University of Singapore.
Levels of IL-4, 11-5, IL-13, eotaxin and IFN-γ in the BAL fluid were measured (IL-4, IL-5 and IFN-γ from BD Biosciences Pharmingen, San Diego, Calif., USA; IL-13 and eotaxin from R&D Systems, Minneapolis, Minn., USA). The kits were obtained from two different manufacturers and thus the protocols differed in certain steps. In brief, 50 μl of coating capture antibody in respective coating buffers (pH 9.5, 0.1 M sodium carbonate for IL-4, IL-5 and IFN-γ; 1×PBS for IL-13 and eotaxin) was coated to 96-well ELISA plate (NUNC, Denmark). The plate was sealed with parafilm and incubated overnight at respective temperature (4° C. for IL-4, IL-5 and IFN-γ and room temperature for IL-13 and eotaxin). Next day, each well was washed with washing buffer (PBS with 0.05% Tween-20) and blocked with 200 μl blocking buffer (PBS with 10% FBS for IL-4, IL-5 and IFN-γ; 1×PBS with 1% BSA and 5% sucrose for IL-13 and eotaxin) for 2 hours at room temperature. After blocking, 50 μl of standards and BAL fluid samples were loaded into respective wells, and incubated for 2 h at room temperature. Several washings were done to remove unbound molecules. The plate was incubated with biotinylated-detection antibody with HRP for 1 h (BD OptEIA™ Kit) or with biotinylated detection antibody for 1 h followed by HRP for 45 min (R&D Kit). After washing, 50 μl of TMB peroxidase substrate (solution A: solution B=9:1) was added into each well, and incubated for 30 min in dark. Lastly, 50 μl of stopping solution (1 M H2SO4) was added to stop the reaction. The optical density of each well in the plate was read at 450 nm with λ correction at 570 nm. Detection limits of the respective kits are as follow: 4 pg/ml for IL-4 and IL-5; 15.6 pg/ml for IL-13 and IFN-γ; and 2 pg/ml for eotaxin.
Mice were anesthetized 24 hours after the last aerosol challenge and bronchoalveolar lavage (BAL) was performed as described above. BAL fluid total and differential cell counts, and cytokine and chemokine levels were determined as described above. Blood was collected by cardiac puncture, and serum levels of total IgE and OVA-specific IgE, IgG1, and IgG2a levels were determined.
Levels of total IgE and OVA-specific IgE, IgG 1 , and IgG2a in serum were measured. 96-well ELISA plate coated with either 50 μl of capture antibody (for total IgE, 1:250 dilution with 1 M Na2CO3) or 50 μl of 20 μg/ml OVA (for OVA-specific IgE, IgG1, and IgG2a) overnight at 4° C. Next day, the plate was washed with washing buffer (PBS with 0.05% Tween-20 for total IgE; PBS with 0.1% Tween-20 for OVA-specific IgE) and blocked with 300 μl 10% FBS in PBS for 2 hr at room temperature. After blocking, standards (only for total IgE) and serum samples were loaded into respective wells and incubated for 2 h. Followed by washing, respective detective antibodies were added and incubated for 1 h, followed by 45 min incubation of HRP-conjugate antibody for 45 min in the dark. Substrates were then added for 30 min in the dark with mild shaking. Lastly, 50 μl of stopping solution (1 M H2SO4) was added to stop the reaction. The optical density of each well in the plate was read at 450 nm with λ correction at 570 nm. The detection limit for total IgE was 2 ng/ml.
Lungs were fixed in 10% neutral formalin, paraffinized, cut into 6-μm sections, and stained with hematoxylin and eosin (H&E) for examining cell infiltration and with periodic acid-Schiff stain (PAS) for measuring mucus production. Quantitative analysis was performed blinded as described below. Mast cells were detected in lung tissue using toluidine-blue staining, and the number of mast cells was counted in paraffin sections. The percentage of degranulated mast cells in the lung was calculated by counting the number of cells with 10% of extrusion of granules.
For both H&E and PAS staining, bronchioles selected for analysis were of similar structure and sizes, with clear morphology presentations and minimum disruptions of the surrounding tissues that could be formed during sectioning. The scoring of inflammatory and globlet cells was performed in 2-4 preparations of each mouse and mean scores were calculated from 4-5 mice. The scoring criteria is summarized in Table 3. Peribronchial cell counts were performed in a blind manner and scored as known in the art. A five-point scoring system (0-4) was adapted: 0, no cells; 1, a few cells; 2, a ring of cells one cell layer deep; 3, a ring of cells two to four cells deep; 4, a ring of cells more than four cells deep. Goblet cell hyperplasia in the airway epithelium was assessed blind and scored according to the percentage of PAS-positive mucus-producing cells. A five-point (0-4) grading system was as follows: 0, no goblet cells; 1, <25%; 2, 25-50%; 3, 50-75%; 4, >75%. Briefly, to determine the severity of inflammatory cell infiltration, peribronchial cell counts were performed blind based on a 5-point scoring system: 0, no cells; 1, a few cells; 2, a ring of cells 1 cell layer deep; 3, a ring of cells 2-4 cells deep; 4, a ring of cells of >4 cells deep. To determine the extent of mucus production, goblet cell hyperplasia in the airway epithelium was quantified blind using a 5-point grading system: 0, no goblet cells; 1, <25%; 2, 25-50%; 3, 50-75%; 4, >75%. Scoring of inflammatory cells and goblet cells was performed in at least 3 different fields for each lung section. Mean scores were obtained from 4 animals. *Significant difference from DMSO control, P<0.05.
Mice were anesthetized and tracheotomy was performed as described above. The internal jugular vein was cannulated and connected to a microsyringe for intravenous methacholine administration. Airway resistance (RI) and dynamic compliance (Cdyn) in response to increasing concentrations of mechacholine were recorded using a whole body plethysmograph chamber (Buxco, Sharon, Conn.) and ventilated mechanically by a ventilator via the tube that was inserted into the trachea at a tidal volume of 200 μl/breadth and a breathing rate of 150/min. Airflow and pressure changes were detected by respective transducers, recorded and analyzed by Biosystem XA software (Buxco, Sharon, Conn., USA). Results are expressed as a percentage of the respective basal values in response to phosphate buffered saline (PBS).
To determine the effects of andrograhpolide on OVA-specific immune responses in lymphocytes, thoracic lymph node cells were grown in bronchial epithelial bulletkit medium (Cambrex BioScience, Walkersvile, Md., USA), supplemented with bovine pituitary extract (2 ml), hydrocortisone (0.5 ml), recombinant human EGF (0.5 ml), epinephrine (0.5 ml), transferrin (0.5 ml), insulin (0.5 ml), retinoic acid (0.5 ml), triiodothyronine (0.5 ml), gentamycin sulfate (50 μg/ml), and amphotericin B (50 ng/ml). The cells were incubated in 5% CO2 incubator at 37° C., and subcultured at 80% to 85% confluency. Cells were exposed to 200 μg/ml OVA for 72 hours. Concanavalin A (Con A, 10 μug/ml) was used as a positive control. Supernatants from parallel triplicate cultures were analyzed for cytokine levels by ELISA. Normal human bronchial epithelial cells were cultured in optimized bronchial epithelial bulletkit medium with supplements (Lonza, Basel, Switzerland). Cells were pretreated with 30 μM andrographolide or vehicle (0.01% DMSO) 4 hours before stimulation with 10 ng/ml tumor necrosis factor (TNF)-α. Total and nuclear proteins, and mRNA were extracted from cells at specified time intervals.
Lung and cell culture nuclear proteins (10 mg per lane) were isolated. Lysates were incubated on ice for 30 min before centrifugation (18,000 g for 5 min). The supernatants were collected, and protein concentrations were determined using a BCA protein assay kit. 28 μl of the protein measured were mixed with 7 μl 5× sample buffer and boiled at 95° C. for 5 min. 10% SDS-PAGE gel was set as known in the art. The gel was placed in a Trans-Blot tank (Bio-Rad Laboratories, Hercules, Calif.). 30 μl of the sample mixtures and Pre-stained SDS Page Marker (Bio-Rad Laboratories, Hercules, Calif.) were loaded into respective wells and ran at 100V for 2 hours. The proteins were then transferred to a PVDF membrane using a semi-dry transblotter (ATTO Corp, Tokyo, Japan). The PVDF membrane was blocked with 5% non-fat milk in Tween-20 Tris buffered saline (TTBS) for 2 hours and probed with various primary antibodies in 1% non-fat milk in TTBS (1:2,000 for anti-rabbit antibodies; 1:5,000 for anti-mouse antibodies; 1:10,000 for β-actin) overnight at 4° C. The PVDF was then washed with TTBS for 10 times (2-3 min each), and incubated in HRP- or AP-conjugated anti-mouse or anti-rabbit antibodies for 1 hour. The membrane was again washed with TTBS. For HRP-conjugated antibody, 1 ml each of HRP substrate 1 and substrate 2 were added onto the membrane. For AP-conjugated antibody, 7.5 ml of AP substrates (300 μl AP 25×Buffer, 75 μl Reagent A, 75 μl Reagent B, 7.5 ml water) was added per gel. The data was then developed in the dark on hyperfilms using an ECL reagent. Immunoblots were probed with anti-p65, anti-phospho-p65 (Ser536), and anti-TATA binding protein (TBP, Abcam, Cambridge, UK).
mRNA Expression
Lungs were isolated from the thoracic cavity 24 hours after the last OVA or saline challenge, and stored in RNAlater. The samples were first incubated at −40° C. overnight for the RNAlater to permeate into the lung tissues to stabilize the RNA. The samples were then stored at −80° C. Before RNA isolation, lung tissues were thawed at −4° C. They were then removed from the RNAlater and immersed in 1 ml Trizol solution. Then, homogenization was performed using a homogenizer (SilentCrusher M, Heidolph Elektro GmbH & Co., Kelheim, Genman). All samples were placed on ice to prevent RNA degradation. The homogenates were then centrifuged at 12,000 g for 10 min at 4° C. The clear RNA containing supernatant was then decanted, incubated for 5 min in room temperature, and 0.2 ml of chloroform was added. All tubes were shaken vigorously for 15 seconds and incubated at room temperature for 3 minutes before being centrifuged at 12,000 g for 15 min at 4° C. About 500 μl of the colourless upper aqueous layer containing RNA, was decanted. 0.5 ml of isopropanol was added and mixed for 30 sec, before being incubated at room temperature for 10 minutes. The tubes were then centrifuged at 12000 rpm for 15 min at 4° C. The supernatant was discarded and 1 ml of 75% ethanol was added to the RNA pellet. Centrifugation at 8500 rpm for 5 minutes at 4° C. was then performed to wash the pellet. The supernatant was again discarded and the washed RNA pellet was air-dried at room temperature for 10 min. The dried RNA pellet was dissolved in 100 μl of ribonuclease-free DEPC water and incubated at 55° C. for 10 minutes. The amount and purity of RNA present in the sample was quantified using the spectrophotometer (NanoDrop ND-1000 from Thermo Risher
Scientific Inc., Waltham, Mass., USA). Both the A260/A280 (DNA/protein) and A260/A230 (DNA/organic contaminants) ratios were recorded as an indication of the purity of the RNA extracted. An acceptable level of purity for both A260/A280 and A260/A230 readings should be about 1.8 to 2.0.
Reverse transcription was performed to synthesize single-stranded complementary DNA (cDNA) templates from the RNA extracted. Volume containing 1 μg total RNA was calculated based on the nucleic acid concentration measured from the spectrophotometer, and was topped up to 20 μl with DEPC water. 10.58 μl of master mix was then added to each sample. Then, cDNA was synthesized from 1 μg of RNA using a multiwall thermal cycler (GeneAmp PCR system 2700 from Applied Biosystems, Foster City, Calif., USA) by bringing the reaction volume to 95° C. for 10 minutes and 42° C. for 30 minutes.
PCR amplifications were then performed using the multiwell thermal cycler on 1 μl cDNA template in a 25 μl reaction volume. The reaction volume contained 10.5 μl nuclease-free water, 0.5 μl forward primer (10 μM), 0.5 μl reverse primer (10 μM) and 12.5 μl 2×PCR master mix (50 units/ml TaqDNA polymerase, 400 μM dATP, 400 μM dGTP, 400 μM dCTP, 400 μM dTTP and 3 mM MgCl2). Primers for inflammatory biomarkers are shown in Table 4.
Nuclear proteins were also analyzed for NF-κB DNA-binding activity using the TransAM p65 transcription factor assay kit (Active Motif, Carlsbad, Calif.).
Data are presented as means±SEM. One-way ANOVA followed by Dunnett's test was used to determine significant differences between treatment groups. Significant levels were set at P<0.05.
Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. The invention includes all such variation and modifications. The invention also includes all of the steps, features, formulations and compounds referred to or indicated in the specification, individually or collectively and any and all combinations or any two or more of the steps or features.
Each document, reference, patent application or patent cited in this text is expressly incorporated herein in their entirety by reference, which means that it should be read and considered by the reader as part of this text. That the document, reference, patent application or patent cited in this text is not repeated in this text is merely for reasons of conciseness.
Any manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention.
The present invention is not to be limited in scope by any of the specific embodiments described herein. These embodiments are intended for the purpose of exemplification only. Functionally equivalent products, formulations and methods are clearly within the scope of the invention as described herein.
The invention described herein may include one or more range of values (eg size, concentration etc). A range of values will be understood to include all values within the range, including the values defining the range, and values adjacent to the range which lead to the same or substantially the same outcome as the values immediately adjacent to that value which defines the boundary to the range.
Throughout this specification, unless the context requires otherwise, the word “comprise” or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers. It is also noted that in this disclosure and particularly in the claims and/or paragraphs, terms such as “comprises”, “comprised”, “comprising” and the like can have the meaning attributed to it in U.S. Patent law; e.g., they can mean “includes”, “included”, “including”, and the like; and that terms such as “consisting essentially of” and “consists essentially of” have the meaning ascribed to them in U.S. Patent law, e.g., they allow for elements not explicitly recited, but exclude elements that are found in the prior art or that affect a basic or novel characteristic of the invention.
Other definitions for selected terms used herein may be found within the detailed description of the invention and apply throughout. Unless otherwise defined, all other scientific and technical terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which the invention belongs.
While the invention has been described with reference to specific methods and embodiments, it will be appreciated that various modifications and changes may be made without departing from the invention.
21. Barnes P J, Adcock I M. How do corticosteroids work in asthma? Ann Intern Med. Sep. 2 2003;139(5 Pt 1):359-370.
58. Barnes P J. Corticosteroid effects on cell signalling. Eur Respir J. February 2006;27(2):413-426.
This application claims benefit of, and priority from, U.S. provisional patent application No. 61/162,861, filed on 24 Mar. 2009, the contents of which are hereby incorporated herein by reference.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/SG10/00113 | 3/24/2010 | WO | 00 | 9/22/2011 |
| Number | Date | Country | |
|---|---|---|---|
| 61162861 | Mar 2009 | US |
